IL17A and neoplasm: Programmed cell death ligand 1 (PD-L1) inhibitors kill tumor cells by triggering pyroptosis (65), while IL-17 promotes PD-L1 expression in tumor cells by PD-1+ immune cell intratumor infiltration (66), suggesting that IL-17 may be a potential target for enhancing the performance of PD-L1 inhibitors by increasing pyroptosis of tumor cells.